B-North: Bridge over troubled waters

Hardman & Co

In this note, we review B-North’s core competitive advantages. We consider how the COVID-19 crisis has i) affected the competitive environment, if anything improving the long-term outlook, ii) affected operational issues for B-North, and iii) had an impact on the timing of the banking licence process. We believe both lending and deposit spreads will be wider, incumbents will be internally focused and customer demand higher. Unlike incumbents, B-North is not facing back-book impairment or management issues. The raising of further equity is the key next step and is likely to reflect the improved outlook.

  • Opportunity improved: We believe increased customer demand, a limited bank appetite to lend and increased risk are all likely to see spreads widen. B-North faces better volume opportunities and wider pricing, without the incumbent profitability drags of lower deposit pricing and back-book impairments.
  • Capital raise: B-North intends to raise equity: £20m required initially for its banking licence, a process we understand is close to completion, and infrastructure, with further amounts to fund growth. In terms of timing, it may raise these funds in a single round or as an initial issue followed by another later in the year.
  • Valuation: Given the growth profile of the company and associated uncertainties, any valuation must be treated with extreme caution. In our initiation report, we gave a range of approaches and sensitivities. Updating these for recent market moves still indicates a market value around three times the equity raised.
  • Risks: Credit risk is key for any bank. B-North will establish independent credit functions, and its technology brings it close to customers interfacing with their internal information. It has multiple options to address any loan growth shortfall. The economic cycle is important. The model is yet to be tested, and capital raised.
  • Investment summary: B-North is still at the pre-revenue stage. Its model should be low-cost and deliver a superior service to customers and intermediaries. It has a conservative credit culture, and uses state-of-the-art technology, written from scratch, to originate, service and manage its business. Funding will be via the deep best-buy retail deposit comparison sites. The potential market is huge, profitable and the opportunity improving. Options to extend the time to a material capital raise have short-term consequences, but do not change the fundamental model.

DOWNLOAD THE FULL REPORT

Share on:
Find more news, interviews, share price & company profile here for:

    Global Opportunities Trust reports 11.9% one year share price return to 31 August

    Global Opportunities Trust has released its August 2025 factsheet, reporting a 12-month NAV increase of 8.8% and a share price gain of 11.8%.

    Dekel Agri-Vision reports 24.5% revenue growth and break-even net profit in H1 2025

    Dekel Agri-Vision posted a stronger performance for the six months ended 30 June 2025, with Group revenue up 24.5% to €23.9m and EBITDA rising 10.7% to €3.1m.

    Aptamer Group to present at ShareSoc Growth Company seminar in Leeds

    Aptamer will present at the ShareSoc Growth Company Seminar on Wednesday, 8 October 2025, at the Leonardo Hotel, Leeds. CEO Dr Arron Tolley and CFO Andrew Rapson will update investors on the Company’s progress, with a recording of the presentation to be published on the Aptamer website after the event.

    Quadrise signs addendum with Valkor to re-phase payments and MMU deliveries

    Quadrise has agreed an addendum to its Site License and Supply Agreement with Valkor Technologies in Utah. The revised terms re-phase the US$1.0 million licence fee through to June 2026 and adjust delivery schedules for Multifuel Manufacturing Units.

    Ampeak Energy reports interim results and financial close of first battery project

    Ampeak Energy has published its unaudited interim results for the six months ended 30 June 2025. The Group focused on achieving financial close of the 240 MWh AW1 battery project at Uskmouth, which was completed in August 2025.

    Nuformix to present NXP002 data at ERS Congress 2025

    Nuformix will attend the European Respiratory Society Congress in Amsterdam from 28 September 2025, where it will present new findings from its lead programme, NXP002, an inhaled treatment for idiopathic pulmonary fibrosis.

      Search

      Search